On-Site Inspecting Zombie Lending
Management Science · 2023-05 · 69 (5) · 2547-2567
DOI: 10.1287/mnsc.2022.4452 ↗Kurz gefasst
Fachartikel in der Zeitschrift Management Science, 2023-05. Verfasst von Diana Bonfim und 3 weiteren Autor:innen. Die Arbeit wurde bisher 57-mal zitiert (Crossref) und nennt 23 Literaturangaben.
Abstract (Originalsprache)
“Zombie lending” remains a widespread practice by banks around the world. In this paper, we exploit a series of large-scale on-site inspections made on the credit portfolios of several Portuguese banks to investigate how these inspections affect banks’ future lending decisions. We find that an inspected bank becomes 20% less likely to refinance zombie firms, immediately spurring their default. Overall, banks seemingly reduce zombie lending because the incentives to hold these loans disappear once they are forced to recognize losses. This paper was accepted by Tomasz Piskorski, finance. Funding: D. Bonfim and G. Cerqueiro acknowledge financial support from Fundação para a Ciência e a Tecnologia [Grants PTDC/EGE-OGE/30314/2017 and UID/GES/00407/2013]. H. Degryse acknowledges financial support from Fonds Wetenschappelijk Onderzoek. S. Ongena acknowledges financial support from the Horizon 2020 European Research Council [Grant ERC ADG 2016 - GA 740272 lending]. Supplemental Material: The data files and online appendix are available at https://doi.org/10.1287/mnsc.2022.4452 .
Zitieren
APA
Bonfim, D., Cerqueiro, G., Degryse, H., & Ongena, S. (2023). On-Site Inspecting Zombie Lending. Management Science, 69(5), 2547-2567. https://doi.org/10.1287/mnsc.2022.4452
Vancouver
Bonfim D, Cerqueiro G, Degryse H, Ongena S. On-Site Inspecting Zombie Lending. Management Science. 2023;69(5):2547-2567. doi:10.1287/mnsc.2022.4452
BibTeX
@article{Bonfim2023,
author = {Bonfim, Diana and Cerqueiro, Geraldo and Degryse, Hans and Ongena, Steven},
title = {On-Site Inspecting Zombie Lending},
journal = {Management Science},
year = {2023},
volume = {69},
number = {5},
pages = {2547--2567},
doi = {10.1287/mnsc.2022.4452}
}
EUVIMED